Gene
PIK3CB
PIK3CB is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (19), Actionable biomarkers (6), Trial mentions (10), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention PIK3CB. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 31 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 1 of 8,738 | 0.01% | not measured | |
| 2025 | 1 of 8,875 | 0.01% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 7 of 11,460 | 0.06% |
| 2022 | 0 of 8,285 | 0.00% | 12 of 13,598 | 0.09% |
| 2021 | 0 of 8,692 | 0.00% | 9 of 15,045 | 0.06% |
| 2020 | 0 of 7,640 | 0.00% | 4 of 14,459 | 0.03% |
| 2019 | 2 of 7,300 | 0.03% | 8 of 12,159 | 0.07% |
| 2018 | 1 of 6,927 | 0.01% | 9 of 11,854 | 0.08% |
| 2017 | 0 of 6,558 | 0.00% | 10 of 11,595 | 0.09% |
Showing 10 of 37 years.
Assay-provider ledger (19)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Affinity | Reagent supplier | Clinical validationAnalytical validation | 1 | October 03, 2025 |
| BIO-RAD | Reagent supplier | Clinical validationAnalytical validation | 1 | October 03, 2025 |
| CWBIO | Reagent supplier | Clinical validationAnalytical validation | 1 | October 03, 2025 |
| General Biosystems | Reagent supplier | Clinical validationAnalytical validation | 1 | October 03, 2025 |
| Keji Biology | Reagent supplier | Clinical validationAnalytical validation | 1 | October 03, 2025 |
Showing 5 of 19 assay-provider companies.
Actionable biomarkers (6)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| PIK3CB (D1067Y) | Pi3k Pathway Inhibitors | responsive | breast adenocarcinoma | Cancer Genome Interpreter |
| PIK3CB (D1067Y) | Mtorc1/2 Inhibitors | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
| PIK3CB (D1067Y) | Akt Inhibitors | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
| PIK3CB oncogenic mutation | Pi3k Pathway Inhibitors | response-associated | head and neck squamous cell carcinoma | Cancer Genome Interpreter |
| PIK3CB oncogenic mutation | Akt Inhibitors | response-associated | head and neck squamous cell carcinoma | Cancer Genome Interpreter |
Showing 5 of 6 actionable-biomarker assertions.
Trial mentions (10)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT01884285 | Trial eligibility (AACT) |
| NCT04001569 | Trial eligibility (AACT) |
| NCT02615730 | Trial eligibility (AACT) |
| NCT06866795 | Trial eligibility (AACT) |
| NCT04439188 | Trial eligibility (AACT) |
Showing 5 of 10 trial mentions.
Target-disease associations (1,177)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 3-hydroxypropylmercapturic acid measurement | measurement | GWAS credible sets |
| 46,XX gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX ovotesticular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX sex reversal 1 | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX testicular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
Showing 5 of 1,177 associations.
Vendor sourcing (31)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV005875503.1 |
| AbbVie Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Children ≥ 2 years and ≤ 18 years of age at the time of first diagnosis and less than 21 years at the time of inclusion 2. Performance status: Karnofsk... | View trial NCT07175415 |
| AbbVie Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | PIK3CB | View trial NCT07175415 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.731A>G (p.Y244C) alteration is located in exon 4 (coding exon 4) of the PIK3CB gene. This alteration results from a A to G substitution at nucleotide p... | View ClinVar record SCV003547599.2 |
| Astrazeneca Plc | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Children ≥ 2 years and ≤ 18 years of age at the time of first diagnosis and less than 21 years at the time of inclusion 2. Performance status: Karnofsk... | View trial NCT07175415 |
Showing 5 of 31 sourcing records.
Trial-cited literature (130)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. | Annals of oncology : official journal of the European Society for Medical Oncology | 2026 | 29 |
| The Inflammation-Energy Metabolism Axis: A Central Driver of Sarcopenia-Osteoporosis: A Narrative Review. | Calcified tissue international | 2026 | 10 |
| Current Status of Research on Losartan in Tumour Therapy. | Journal of cellular and molecular medicine | 2026 | 6 |
| Organoid Modeling and Single-Cell Profiling Reveal Smooth Muscle Cell Migration in Moyamoya Disease. | Communications biology | 2026 | 1 |
| Precision Medicine Program in Chinese Pediatric Patients With Sarcoma. | JCO precision oncology | 2026 | 0 |
Showing 5 of 130 papers.
Protein variant mentions (1)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.E1051K | 1 | 2023 | PMID 37036671 |
Human sample screening reference (6)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.E1051K | ALCHEMIST-ALCH | Not Reported; Not Reported | 2 | 1,170 | 0.17% | 0.05% to 0.62% |
| p.E1051K | HCMI-CMDC | Ductal and Lobular Neoplasms; Complex Mixed and Stromal Neoplasms; Blood Vessel Tumors; Fibromatous Neoplasms; Epithelial Neoplasms, NOS; Mature T- and NK-Cell Lymphomas; Transitional Cell Papillomas and Carcinomas; Complex Epithelial Neoplasms; Squamous Cell Neoplasms; Soft Tissue Tumors and Sarcomas, NOS; Lymphoid Leukemias; Cystic, Mucinous and Serous Neoplasms; Gliomas; Myomatous Neoplasms; Neuroepitheliomatous Neoplasms; Malignant Lymphomas, NOS or Diffuse; Acinar Cell Neoplasms; Osseous and Chondromatous Neoplasms; Synovial-like Neoplasms; Miscellaneous Bone Tumors; Nevi and Melanomas; Adenomas and Adenocarcinomas; Other and unspecified parts of tongue; Stomach; Bronchus and lung; Larynx; Uterus, NOS; Kidney; Esophagus; Other and ill-defined sites; Skin; Colon; Thyroid gland; Bladder; Adrenal gland; Eye and adnexa; Gallbladder; Connective, subcutaneous and other soft tissues; Rectosigmoid junction; Breast; Pancreas; Small intestine; Corpus uteri; Other and unspecified parts of mouth; Liver and intrahepatic bile ducts; Nasal cavity and middle ear; Hematopoietic and reticuloendothelial systems; Brain; Other and unspecified parts of biliary tract; Bones, joints and articular cartilage of other and unspecified sites; Rectum; Unknown; Lymph nodes; Ovary | 1 | 606 | 0.17% | 0.03% to 0.93% |
| p.E1051K | TCGA-BRCA | Cystic, Mucinous and Serous Neoplasms; Adenomas and Adenocarcinomas; Fibroepithelial Neoplasms; Basal Cell Neoplasms; Ductal and Lobular Neoplasms; Epithelial Neoplasms, NOS; Squamous Cell Neoplasms; Complex Epithelial Neoplasms; Adnexal and Skin Appendage Neoplasms; Breast | 1 | 1,098 | 0.09% | 0.02% to 0.51% |
| p.E1051K | TCGA-GBM | Gliomas; Not Reported; Brain | 1 | 601 | 0.17% | 0.03% to 0.94% |
| p.E1051K | TCGA-SKCM | Nevi and Melanomas; Skin; Connective, subcutaneous and other soft tissues; Lymph nodes; Nasal cavity and middle ear; Vulva; Breast; Bones, joints and articular cartilage of other and unspecified sites; Retroperitoneum and peritoneum; Vagina; Colon; Adrenal gland; Corpus uteri; Other and ill-defined sites; Liver and intrahepatic bile ducts; Anus and anal canal; Spinal cord, cranial nerves, and other parts of central nervous system; Small intestine; Bronchus and lung; Brain; Parotid gland | 1 | 470 | 0.21% | 0.04% to 1.20% |
Showing 5 of 6 cohort observations.
Literature-extracted relations (30)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Lipopolysaccharides | Chemical | associate |
Promotion of Epithelial Healing in Oral Mucositis by hESC-derived Mesenchymal Stem Cells <i>via</i> the PI3K/AKT Pathway. | 2025 |
| Aspirin | Chemical | associate |
Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer. | 2025 |
| Aspirin | Chemical | negative_correlate |
Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man. | 2015 |
| CLOPIDOGREL | Chemical | associate |
Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man. | 2015 |
| ADENOSINE TRIPHOSPHATE | Chemical | associate |
Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor. | 2012 |
Showing 5 of 30 relation assertions.
Organizations publishing (240)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 14 | 2015 to 2025 |
| The University of Texas System | Academic | 13 | 2010 to 2025 |
| Dana-Farber Cancer Institute | Other | 10 | 2009 to 2025 |
| CERCA Institution | Government | 5 | 2012 to 2025 |
| Government of the United States of America | Government | 5 | 2017 to 2025 |
Showing 5 of 240 organizations.
Where PIK3CB appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- psychiatric disorder
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
1,082 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.